Drug Profile
RG 2077
Alternative Names: CTLA4-Ig - Repligen; CTLA4-IG4m; RG1046; RG2077Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Repligen
- Class Immunoglobulin fusion proteins; Recombinant fusion proteins
- Mechanism of Action CD80 antigen inhibitors; IgE receptor antagonists; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Graft-versus-host disease; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 11 Aug 2005 No development reported - Phase-I for Graft-versus-host disease in USA (unspecified route)
- 11 Aug 2005 No development reported - Phase-I for Idiopathic thrombocytopenic purpura in United Kingdom (unspecified route)
- 11 Aug 2005 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)